Diabetes and CKD: Strategies for Diagnosis and Treatment
May 21, 2024 - 00:11:00
Radio and PodcastLive Radio & PodcastsScience & Medicine
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients
Host: Carol Wysham Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in p...
About This Episode
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients is an episode from Diabetes Discourse by ReachMD. Host: Carol Wysham Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardi...
Podcast
This episode belongs to Diabetes Discourse.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Apr 8, 2024, 00:11:30 long, audio available.
Related Episodes
Continue listening to more episodes from Diabetes Discourse.
Uncovering the Prevalence of Type 1 Diabetes in Older Adults
May 9, 2024 - 00:07:30
Concentrating on the MOMPOD Trial for Metformin Plus Insulin
Apr 12, 2024 - 00:10:30
Utilizing Hybrid Closed-Loop Technology for T1D Pediatric Patients
Apr 9, 2024 - 00:07:00
Overcoming Obesity: Insights from the SURMOUNT-4 Trial
Mar 27, 2024 - 00:12:30
Strategies for Addressing Diabetes Stigma and Discrimination
Feb 1, 2024 - 00:11:00
How the Artificial Pancreas Can Help Diabetic Patients
Dec 20, 2023 - 00:03:00
Using CGMs and Insulin Pumps to Treat Pediatric Patients with T1D
Dec 19, 2023 - 00:04:30
Questions About This Episode
What is Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients about?
Host: Carol Wysham Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Where can I listen to Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients?
You can listen to Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients from?
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients is an episode from Diabetes Discourse by ReachMD.
How long is this episode?
This episode is 00:11:30 long.
When was this episode published?
This episode was published on Apr 8, 2024.
Can I save Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from Diabetes Discourse?
Yes. This page shows related episodes from Diabetes Discourse when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients?
You can listen to Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients is from Diabetes Discourse by ReachMD.
What are the episode details?
Published Apr 8, 2024 and 00:11:30 long